Avacta Therapeutics (LSE:AVCT) has presented updated clinical results for its lead oncology candidate, faridoxorubicin (AVA6000), at the ASCO 2026 meeting, reporting encouraging safety and efficacy outcomes in patients with salivary gland cancer. AVA6000 is a pre|CISION-enabled version of doxorubicin designed to activate selectively within the tumour environment, with the goal of reducing systemic toxicity while maintaining anti-cancer activity.
The latest Phase 1a/1b findings suggest the treatment continues to demonstrate a favourable safety profile, even at dose levels approaching three times those typically associated with conventional doxorubicin therapy. The data support further development of the candidate as it moves toward later-stage clinical evaluation.
Early Clinical Responses Observed in Salivary Gland Cancer
Among 38 evaluable patients enrolled in the salivary gland cancer expansion cohort, the company reported four confirmed partial responses and nine minor responses. Overall disease control reached 92%, with several patients continuing treatment or remaining under follow-up observation.
Management believes these findings provide early evidence of anti-tumour activity in a patient population with limited treatment options and reinforce the potential of the pre|CISION platform.
Data Suggest Reduced Cardiac Risk
A key focus of the update was the cardiac safety profile of AVA6000. Pharmacokinetic and exposure-response analyses indicated that the release of doxorubicin from the drug avoids the high systemic concentration peaks typically associated with standard formulations.
The company reported no meaningful relationship between drug exposure and deterioration in cardiac function. These findings contributed to regulators removing the previous lifetime exposure cap, a development that may allow patients to receive longer treatment durations.
Importantly, Avacta reported no cases of severe cardiotoxicity or cardiomyopathy among 111 treated patients, including individuals who exceeded historical cumulative exposure limits associated with conventional doxorubicin.
Platform Differentiation Continues to Strengthen
The clinical data are seen as further validation of Avacta’s pre|CISION technology, which is designed to improve the therapeutic index of established chemotherapy agents by targeting drug activation within tumours.
The company plans to continue patient enrolment and expects to provide additional updates later in June at the BIO International Convention. Investors and clinicians will be monitoring future results closely as Avacta seeks to establish the platform as a potential next-generation approach to chemotherapy delivery.
Outlook Balances Clinical Progress and Financial Challenges
While the AVA6000 programme continues to generate positive clinical momentum, Avacta’s broader outlook remains influenced by ongoing financial pressures, including operating losses, cash consumption and balance-sheet constraints.
Technical indicators provide some support, with the shares trading above longer-term averages and momentum measures remaining positive. However, valuation remains difficult to assess given the company’s negative earnings profile and absence of dividend payments. Progress in clinical development and prudent cash management offer encouraging signs, although future financing requirements, partnership activity and development timelines remain important considerations.
More about Avacta Group plc
Avacta Therapeutics, a division of Avacta Group plc, is a clinical-stage biotechnology company focused on developing oncology therapies through its proprietary pre|CISION drug delivery platform. The technology is designed to activate chemotherapy agents within the tumour microenvironment, potentially reducing systemic side effects while enhancing treatment effectiveness. The company’s pipeline targets multiple cancer indications, including salivary gland cancer and soft tissue sarcoma, with the aim of improving outcomes through more precise delivery of established anti-cancer drugs.
Leave a Reply